Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction

Heart failure (HF) is a clinical condition caused by structural or functional heart abnormalities. The increasing prevalence of HF and frequent hospitalisation due to HF (hHF) significantly impact healthcare expenditure. Moreover, there is limited data on the economic burden of HF across different e...

Full description

Saved in:

Bibliographic Details
Main Author:	Low, Joo Zheng
Format:	Thesis
Language:	English
Published:	2023
Subjects:	RS1-441 Pharmacy and materia medica
Online Access:	http://eprints.usm.my/60496/1/LOW%20JOO%20ZHENG%20-%20TESIS24.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.60496
record_format	uketd_dc
spelling	my-usm-ep.604962024-05-02T09:29:52Z Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction 2023-09 Low, Joo Zheng RS1-441 Pharmacy and materia medica Heart failure (HF) is a clinical condition caused by structural or functional heart abnormalities. The increasing prevalence of HF and frequent hospitalisation due to HF (hHF) significantly impact healthcare expenditure. Moreover, there is limited data on the economic burden of HF across different ejection fractions (EF). Empagliflozin is a novel antidiabetic medication that improves clinical outcomes of HF with reduced ejection fraction (HFrEF) patients. Therefore, this study was designed to determine the cost of HF treatment, cost-effectiveness, and budget impact of adding empagliflozin to the standard of care (SoC) compared to SoC monotherapy from the Ministry of Health Malaysia perspective. A prevalence-based, bottom-up cost analysis study was conducted in three tertiary hospitals in Malaysia to estimate the direct cost and resource utilisation throughout a one-year follow-up. The total costs consisted of outpatient, hospitalisation, medications, laboratory tests, and procedure costs, categorised according to ejection fraction. The cost-effectiveness of empagliflozin was determined using a cohort-based transition states model with health states defined as Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score quartiles and death. The lifetime direct medical costs and quality-adjusted life-years (QALYs) were compared, and the incidence of death and hHF were modelled for each monthly cycle. The clinical inputs and utilities were estimated from the EMPEROR-Reduced trial and supplemented by local costing data. 2023-09 Thesis http://eprints.usm.my/60496/ http://eprints.usm.my/60496/1/LOW%20JOO%20ZHENG%20-%20TESIS24.pdf application/pdf en public masters Universiti Sains Malaysia Pusat Pengajian Sains Farmasi
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	RS1-441 Pharmacy and materia medica
spellingShingle	RS1-441 Pharmacy and materia medica Low, Joo Zheng Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction
description	Heart failure (HF) is a clinical condition caused by structural or functional heart abnormalities. The increasing prevalence of HF and frequent hospitalisation due to HF (hHF) significantly impact healthcare expenditure. Moreover, there is limited data on the economic burden of HF across different ejection fractions (EF). Empagliflozin is a novel antidiabetic medication that improves clinical outcomes of HF with reduced ejection fraction (HFrEF) patients. Therefore, this study was designed to determine the cost of HF treatment, cost-effectiveness, and budget impact of adding empagliflozin to the standard of care (SoC) compared to SoC monotherapy from the Ministry of Health Malaysia perspective. A prevalence-based, bottom-up cost analysis study was conducted in three tertiary hospitals in Malaysia to estimate the direct cost and resource utilisation throughout a one-year follow-up. The total costs consisted of outpatient, hospitalisation, medications, laboratory tests, and procedure costs, categorised according to ejection fraction. The cost-effectiveness of empagliflozin was determined using a cohort-based transition states model with health states defined as Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score quartiles and death. The lifetime direct medical costs and quality-adjusted life-years (QALYs) were compared, and the incidence of death and hHF were modelled for each monthly cycle. The clinical inputs and utilities were estimated from the EMPEROR-Reduced trial and supplemented by local costing data.
format	Thesis
qualification_level	Master's degree
author	Low, Joo Zheng
author_facet	Low, Joo Zheng
author_sort	Low, Joo Zheng
title	Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction
title_short	Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction
title_full	Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction
title_fullStr	Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction
title_full_unstemmed	Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction
title_sort	cost evaluation of heart failure treatment, cost-effectiveness analysis and budget impact of adding empagliflozin to standard treatment for heart failure with reduced ejection fraction
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Farmasi
publishDate	2023
url	http://eprints.usm.my/60496/1/LOW%20JOO%20ZHENG%20-%20TESIS24.pdf
_version_	1804888948893286400

Cost Evaluation Of Heart Failure Treatment, Cost-effectiveness Analysis And Budget Impact Of Adding Empagliflozin To Standard Treatment For Heart Failure With Reduced Ejection Fraction

Similar Items